Literature DB >> 20542001

Negative regulation of tumor suppressor p53 by microRNA miR-504.

Wenwei Hu1, Chang S Chan, Rui Wu, Cen Zhang, Yvonne Sun, Jun S Song, Laura H Tang, Arnold J Levine, Zhaohui Feng.   

Abstract

Tumor suppressor p53 plays a central role in tumor prevention. p53 protein levels and activity are under a tight and complex regulation in cells to maintain the proper function of p53. MicroRNAs play a key role in the regulation of gene expression. Here we report the regulation of p53 through miR-504. miR-504 acts as a negative regulator of human p53 through its direct binding to two sites in the p53 3' untranslated region. Overexpression of miR-504 decreases p53 protein levels and functions in cells, including p53 transcriptional activity, p53-mediated apoptosis, and cell-cycle arrest in response to stress, and furthermore promotes tumorigenecity of cells in vivo. These results demonstrate the direct negative regulation of p53 by miR-504 as a mechanism for p53 regulation in cells, which highlights the importance of microRNAs in tumorigenesis. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542001      PMCID: PMC2900922          DOI: 10.1016/j.molcel.2010.05.027

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  45 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  Chromosomal changes pattern and gene amplification in T cell non-Hodgkin's lymphomas.

Authors:  M Renedo; B Martinez-Delgado; E Arranz; M Garcia; M Urioste; A Martinez-Ramirez; C Rivas; J C Cigudosa; I Benitez
Journal:  Leukemia       Date:  2001-10       Impact factor: 11.528

Review 3.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 4.  Mechanisms of gene silencing by double-stranded RNA.

Authors:  Gunter Meister; Thomas Tuschl
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

5.  A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions.

Authors:  R Higuchi; B Krummel; R K Saiki
Journal:  Nucleic Acids Res       Date:  1988-08-11       Impact factor: 16.971

6.  CD44 is a potential target of amplification within the 11p13 amplicon detected in gastric cancer cell lines.

Authors:  Y Fukuda; N Kurihara; I Imoto; K Yasui; M Yoshida; K Yanagihara; J G Park; Y Nakamura; J Inazawa
Journal:  Genes Chromosomes Cancer       Date:  2000-12       Impact factor: 5.006

7.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

8.  Reduced accumulation of specific microRNAs in colorectal neoplasia.

Authors:  Michael Z Michael; Susan M O' Connor; Nicholas G van Holst Pellekaan; Graeme P Young; Robert J James
Journal:  Mol Cancer Res       Date:  2003-10       Impact factor: 5.852

9.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

10.  Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.

Authors:  C Deng; P Zhang; J W Harper; S J Elledge; P Leder
Journal:  Cell       Date:  1995-08-25       Impact factor: 41.582

View more
  136 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 3.  Crosstalk between the DNA damage response pathway and microRNAs.

Authors:  Cecil Han; Guohui Wan; Robert R Langley; Xinna Zhang; Xiongbin Lu
Journal:  Cell Mol Life Sci       Date:  2012-03-20       Impact factor: 9.261

Review 4.  MicroRNAs: new players in the DNA damage response.

Authors:  Hailiang Hu; Richard A Gatti
Journal:  J Mol Cell Biol       Date:  2010-12-23       Impact factor: 6.216

Review 5.  Making sense of ubiquitin ligases that regulate p53.

Authors:  Abhinav K Jain; Michelle Craig Barton
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

6.  A small kiss of death for cancer.

Authors:  Angelika Eggert; Johannes H Schulte
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

Review 7.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

8.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

9.  Non-coding RNAs in DNA damage response.

Authors:  Yunhua Liu; Xiongbin Lu
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

10.  Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.

Authors:  Xinlong Ma; Koji Yoshimoto; Yaulei Guan; Nobuhiro Hata; Masahiro Mizoguchi; Noriaki Sagata; Hideki Murata; Daisuke Kuga; Toshiyuki Amano; Akira Nakamizo; Tomio Sasaki
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.